Liang Cheng, Director of Anatomic and Molecular Pathology at Brown Pathology and Laboratory Medicine, shared on LinkedIn:
“Very happy to share newest online publication in JAMA Oncology JAMAOnc, ‘FGFR Alterations in Bladder Cancer- From Molecular Pathogenesis to Precision Oncology,’ written by Dr. Katrina Collins.
In this review, we examine how FGFR biology is reshaping the molecular classification and precision management of patients with bladder cancer. We highlight the central role of FGFR3 alterations and the fast-growing range of molecular biomarker testing at every stage of disease. We discuss comprehensive genomic profiling, liquid biopsy (including urine-based molecular testing), and emerging molecular residual disease (MRD) assessment.
We also cover how each is used in diagnosis, treatment selection, surveillance, and disease monitoring.
On the therapeutic front, erdafitinib has established FGFR-directed precision therapy in advanced urothelial carcinoma. Combination approaches, intravesical FGFR-directed treatments, and next-generation FGFR3-selective inhibitors are extending this strategy into new clinical settings. Emerging technologies, including AI-assisted histopathology and integrated multi-omic biomarkers, may further refine patient selection.”
Title: FGFR Alterations in Bladder Cancer—From Molecular Pathogenesis to Precision Oncology
Authors: Katrina Collins, MD1; Liang Cheng
Other articles about Liang Cheng on OncoDaily.
